Clinical Trial Update: Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating fluorine-18 fluoride PET to assess response to dasatinib in hormone-resistant metastatic prostate cancer with bone metastases;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Status: COMPLETED | Results posted: 2015-07-16